EU member states' pharmacy policy leads to ECJ showdown

3 August 2008

The tensions between European Union members states over the liberalization of pharmaceutical distribution systems are the topic of a special report by the German pharmacy trade publication APOTHEKE ADHOC. Patrick Hollstein, the editor in chief for the project, explains that, "in several cases, the European Commission and national courts have appealed to the European Court of Justice for judgement on national pharmacy law. Within the coming months, EU judges will be occupied with German, Italian and Spanish pharmacy law" (Marketletter July 21).

The publication, titled Showdown in Luxembourg: Pharmacies in the sight of the EU, also examines ongoing cases against national authorities in Austria, Bulgaria, France, Germany, Portugal and Spain. The report's authors argue that the demands of the internal European market for cross-border harmonization of rules and open access to previously-closed markets for major drug distribution firms will undermine the professional standards of the pharmacy business.

Mr Hollstein argues that decisions on the future of drug distribution are not being determined by pharmacists or consumers, but by "interest groups, ambitious lawyers and laissez-faire politicians." The report includes a timetable of the infringement proceedings by the EC against member states, a country-by-country guide to the issues raised. It also includes a series of interviews with regulators, politicians and a member of the Pharmaceutical Group of the EU. There is also a summary of all the European nations' pharmacy systems, including some outside the Union.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight